Market Cap | 93.09M | P/E | - | EPS this Y | 36.20% | Ern Qtrly Grth | - |
Income | -49.5M | Forward P/E | -1.96 | EPS next Y | 6.70% | 50D Avg Chg | -18.00% |
Sales | 654k | PEG | - | EPS past 5Y | - | 200D Avg Chg | -33.00% |
Dividend | N/A | Price/Book | N/A | EPS next 5Y | - | 52W High Chg | -82.00% |
Recommedations | 2.00 | Quick Ratio | 1.44 | Shares Outstanding | 128.43M | 52W Low Chg | 2.00% |
Insider Own | 40.11% | ROA | -52.33% | Shares Float | 66.77M | Beta | 0.49 |
Inst Own | 19.15% | ROE | -595.47% | Shares Shorted/Prior | 148.45K/262.48K | Price | 0.73 |
Gross Margin | 81.50% | Profit Margin | - | Avg. Volume | 510,761 | Target Price | 5.00 |
Oper. Margin | -5,841.18% | Earnings Date | May 10 | Volume | 165,338 | Change | -2.03% |
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company also develops CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease and to provide immune support for symptom resolution. In addition, it markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.
HC Wainwright & Co. | Buy | Apr 17, 24 |
Benchmark | Buy | Mar 20, 24 |
HC Wainwright & Co. | Buy | Mar 13, 24 |
HC Wainwright & Co. | Buy | Mar 11, 24 |
HC Wainwright & Co. | Buy | Feb 22, 24 |
HC Wainwright & Co. | Buy | Dec 21, 23 |
HC Wainwright & Co. | Buy | Sep 21, 23 |
HC Wainwright & Co. | Buy | Aug 29, 23 |
Roth MKM | Buy | Aug 29, 23 |
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
MATLIN DAVID J | Director Director | Nov 10 | Buy | 0.41 | 250,002 | 102,501 | 7,043,686 | 11/13/23 |
Stevens John Henry | Director Director | Jun 26 | Buy | 0.80 | 316,455 | 253,164 | 800,204 | 06/27/23 |
Etherington Robert Dee | Chief Executive Offi.. Chief Executive Officer | Jun 26 | Buy | 0.81 | 25,000 | 20,250 | 25,000 | 06/27/23 |
Mosca Alison | Director Director | Jun 16 | Buy | 0.80 | 2,394,375 | 1,915,500 | 3,238,375 | 06/20/23 |
Gay Jonathon | Director Director | Jun 16 | Buy | 0.80 | 105,625 | 84,500 | 105,625 | 06/20/23 |
MATLIN DAVID J | Director Director | Jun 16 | Buy | 0.80 | 1,500,000 | 1,200,000 | 6,793,684 | 06/20/23 |
MATLIN DAVID J | Director Director | Nov 02 | Buy | 1.01 | 2,871,287 | 2,900,000 | 5,293,684 | 11/03/22 |
Gay Jonathon | Director Director | Nov 02 | Buy | 1.01 | 990,099 | 1,000,000 | 2,154,848 | 11/03/22 |
Ugwumba Chidozie | Director Director | Nov 02 | Buy | 1.01 | 990,099 | 1,000,000 | 5,518,908 | 11/03/22 |
Mosca Alison | Director Director | Nov 02 | Buy | 1.01 | 792,079 | 800,000 | 844,000 | 11/03/22 |
Stevens John Henry | Director Director | Nov 02 | Buy | 1.01 | 148,515 | 150,000 | 483,749 | 11/03/22 |
MATLIN DAVID J | Director Director | Jun 16 | Buy | 2.51 | 149,610 | 375,521 | 2,422,397 | 06/21/22 |
Mosca Alison | Director Director | Jun 15 | Buy | 2.62 | 5,000 | 13,100 | 39,476 | 06/16/22 |
MATLIN DAVID J | Director Director | Jun 14 | Buy | 2.66 | 96,011 | 255,389 | 2,272,787 | 06/16/22 |
MATLIN DAVID J | Director Director | Jun 13 | Buy | 3.06 | 55,000 | 168,300 | 2,176,776 | 06/14/22 |
MATLIN DAVID J | Director Director | Jun 03 | Buy | 2.52 | 60,670 | 152,888 | 2,121,776 | 06/07/22 |
MATLIN DAVID J | Director Director | May 27 | Buy | 2.27 | 35,000 | 79,450 | 2,061,106 | 05/27/22 |
General Resonance LLC | 10% Owner 10% Owner | May 16 | Sell | 2.2 | 181,818 | 400,000 | 15,560,212 | 05/18/22 |
MATLIN DAVID J | Director Director | May 16 | Buy | 2.20 | 181,818 | 400,000 | 2,026,106 | 05/18/22 |
Glanzman Robert | Chief Medical Office.. Chief Medical Officer | May 16 | Sell | 2.03 | 4,717 | 9,576 | 10,564 | 05/18/22 |
Gay Jonathon | Director Director | May 16 | Buy | 2.08 | 10,000 | 20,800 | 68,745 | 05/17/22 |
WILCOX REED N | Director Director | May 02 | Option | 0.15 | 100,000 | 15,000 | 400,233 | 05/03/22 |
MATLIN DAVID J | Director Director | Apr 20 | Buy | 3.01 | 132,891 | 400,002 | 1,844,288 | 04/21/22 |
MATLIN DAVID J | Director Director | Mar 28 | Buy | 3.17 | 18,648 | 59,114 | 1,711,397 | 03/30/22 |
MATLIN DAVID J | Director Director | Mar 23 | Buy | 2.97 | 40,000 | 118,800 | 1,692,749 | 03/25/22 |
MATLIN DAVID J | Director Director | Mar 18 | Buy | 2.85 | 55,000 | 156,750 | 1,652,749 | 03/22/22 |
General Resonance LLC | 10% Owner 10% Owner | Feb 01 | Sell | 2.96 | 101,352 | 300,002 | 15,874,921 | 02/03/22 |
MATLIN DAVID J | Director Director | Feb 01 | Buy | 2.96 | 101,352 | 300,002 | 1,597,749 | 02/02/22 |
WILCOX REED N | Director Director | Jan 20 | Option | 0.15 | 253,000 | 37,950 | 300,233 | 01/20/22 |